Q-omics provides the consensus-scored SLC15A5 profile across patient tissues and cancer cell-line models. SLC15A5 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC15A5 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, SLC15A5 RNA expression shows 6,924 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, KICH, and STAD as cancer lineages where SLC15A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC15A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC15A5 survival associations across molecular data types. SLC15A5 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC15A5 RNA expression–survival associations across cancer types. High SLC15A5 expression shows unfavorable associations in READ and KIRC, but favorable associations in ACC, LGG, LAML and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC15A5 RNA expression.
This table summarizes SLC15A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC15A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC15A5 shows lower tumor expression in KICH, BRCA and LUSC and higher tumor expression in KIRC. The KICH box plot shows higher SLC15A5 RNA expression in normal versus tumor tissue (log2 FC = −0.038, t-test p < 0.001).
This table shows molecular features associated with SLC15A5 in patient tissues and cancer cell lines. In patient samples, SLC15A5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC15A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
